Daraxonrasib and Cancer ♋

Daraxonrasib is an experimental targeted therapy that fights pancreatic cancer by “turning off” a protein that acts like a broken growth switch inside cancer cells. 

• The Problem: In about 90% of pancreatic cancers, a protein called RAS (often KRAS) develops a mutation. Normally, this protein acts as a switch that tells cells when to grow. In cancer, the switch gets stuck in the “ON” position, sending a constant, out-of-control signal for cells to multiply and spread.
• The “Molecular Glue” Solution: For decades, scientists found this “on” switch impossible to grab onto (calling it “undruggable”). Daraxonrasib works by pairing up with another protein already in your body (cyclophilin A) to create a “molecular glue”. This duo can finally latch onto the active RAS protein and physically block it from sending growth signals. 
• Pan-RAS Targeting: While some drugs only target one specific type of mutation, daraxonrasib is a “pan-RAS” inhibitor. It can block many different versions of the RAS mutation (like G12D, G12V, and G12R), making it effective for a much wider range of patients.
• Targets the “ON” State: Many older experimental drugs tried to catch the protein while it was “off.” Daraxonrasib is designed to hit the protein while it is actively driving the cancer. 
• Survival Impact: In a major Phase 3 clinical trial (RASolute 302), the drug nearly doubled the overall survival time for patients with advanced pancreatic cancer compared to standard chemotherapy—increasing it from roughly 6.7 months to 13.2 months.
• Availability: As of May 2026, the drug is not yet fully FDA-approved but is being fast-tracked. The FDA recently authorized an Expanded Access Program (EAP), allowing some eligible patients to access the drug while the final approval process continues.